Organization
Université Paris Saclay
4 abstracts
Abstract
Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in metastatic renal cell carcinoma (RCC): Primary PFS analysis from the phase 3, randomized, open-label CONTACT-03 study.Org: Dana-Farber Cancer Institute, Gustave Roussy Cancer Center, Clinical Hospital No. 1 of the Poznan University of Medical Sciences, Memorial Sloan Kettering Cancer Center, Hospital Universitario 12 de Octubre,
Abstract
Chemotherapy and liver transplantation versus chemotherapy alone in patients with definitively unresectable colorectal liver metastases: A prospective multicentric randomized trial (TRANSMET).Org: Assistance Publique - Hôpitaux de Paris (APHP), University Paris-Saclay, Clinical Research Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy, Service de Chirurgie HPB Transplantation, Hopital Haut Leveque,
Abstract
Circulating kidney injury molecule-1 (KIM-1) biomarker analysis in IMmotion010: A randomized phase 3 study of adjuvant (adj) atezolizumab (atezo) vs placebo (pbo) in patients (pts) with renal cell carcinoma (RCC) at increased risk of recurrence after resection.Org: Gustave Roussy Cancer Center, Université Paris Saclay, Paris, France, Royal Free London NHS Foundation Trust, UCL Division of Surgery and Interventional Science,
Abstract
Phase 1/2 study of tusamitamab ravtansine in patients with advanced solid tumors: Pooled safety analysis of corneal adverse events.Org: Gustave Roussy Département d'Organisation du Parcours Patient, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Institut Bergonié, Aix Marseille University - Assistance Publique Hopitaux De Marseille, Université Paris Saclay,